Page last updated: 2024-12-07

sch 28080

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sch 28080: not related structurally to other known anti-ulcer agents; inhibits histamine-stimulated gastric secretion; prevents gastric lesions induced by aspirin, indomethacin & ethanol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108137
CHEMBL ID47529
CHEBI ID92978
SCHEMBL ID1815961
MeSH IDM0108108

Synonyms (66)

Synonym
sch28080
HMS3268O05
BRD-K55748775-001-01-4
sch-28080
EU-0100439
sch-28080, >=98% (hplc), solid
lopac-s-4443
tocris-1690
NCGC00025259-01
NCGC00015953-01
2-methyl-8-(phenylmethoxy)imidazo-(1-2-a)pyrine-3-acetonitrile
imidazo(1,2-a)pyridine-3-acetonitrile, 2-methyl-8-(phenylmethoxy)-
schering compound 28080
NCGC00025259-03
sch 28080
NCGC00025259-02
s28080 ,
NCGC00015953-03
S 4443
2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-acetonitrile
NCGC00015953-05
CHEMBL47529 ,
bdbm50008977
(8-benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrie
(8-benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile
2-(8-(benzyloxy)-2-methylimidazo[1,2-a]pyridin-3-yl)acetonitrile
76081-98-6
2-(2-methyl-8-phenylmethoxyimidazo[1,2-a]pyridin-3-yl)acetonitrile
HMS3261G20
CCG-204531
NCGC00015953-02
NCGC00015953-04
FT-0641585
unii-00427x161i
00427x161i ,
LP00439
NCGC00261124-01
tox21_500439
DTXSID10226971
8-benzyloxy-3-cyanomethyl-2-methyl-imidazo[1,2-a]pyridine
PYKJFEPAUKAXNN-UHFFFAOYSA-N ,
8-benzyloxy-3-cyanomethyl-2-methylimidazo[1,2-a]pyridine
SCHEMBL1815961
2-methyl-8-(phenylmethoxy)imidazo(1,2-a)-pyridine-3-acetonitrile
c17h15n3o
HB1124
AKOS024456748
CHEBI:92978
(8-benzyloxy-2-methylimidazo[1,2-a]pyridin-3-yl)acetonitrile
SR-01000076230-3
sr-01000076230
SR-01000076230-1
Q27164711
Z2044772151
HMS3678M11
2-methyl-8 (phenyl-methoxy) imidazo (1,2-a)-pyridine-3-acetonitrile
HY-103261
HMS3414M11
SDCCGSBI-0050424.P002
NCGC00015953-08
CS-0026715
2-methyl-8-(phenylmethoxy)-imidazo[1,2-a]pyridine-3-acetonitrile
MS-23941
EN300-233396
2-[8-(benzyloxy)-2-methylimidazo[1,2-a]pyridin-3-yl]acetonitrile
BDA08198

Research Excerpts

Overview

SCH 28080 is an H+K(+)-ATPase specific inhibitor. It binds to the high affinity K+ site.

ExcerptReferenceRelevance
"SCH 28080 is an H+,K(+)-ATPase specific inhibitor and binds to the high affinity K+ site."( The apical chloride channel as part of the function of gastric H+,K(+)-ATPase.
Asano, S; Morii, M; Ohshika, M; Takeguchi, N; Tomiyama, Y, 1994
)
1.01

Effects

ExcerptReferenceRelevance
"SCH 28080 has no effect on Mg2(+)-catalyzed dephosphorylation."( Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.
Mendlein, J; Sachs, G, 1990
)
1

Dosage Studied

ExcerptRelevanceReference
"8 mM Ca2+, the rate of glycogen breakdown was increased by theophylline in a dose-dependent manner and the dose-response curve was somewhat similar to that obtained with oxygen uptake."( Ca2+ requirement for metabolic effects of secretagogues in the amphibian gastric mucosa.
Chacín, J; Lobo, P; Subero, O, 1989
)
0.28
" dosing of SCH 28080, 1 mg/kg, indicating that the antisecretory action of SCH 28080 was not secondary to changes in gastric blood flow."( Studies on the mechanisms of the antisecretory and cytoprotective actions of SCH 28080.
Barnett, A; Casciano, C; Chiu, PJ; Long, JF; Tetzloff, G, 1983
)
0.88
" showed moderate effects, but the dosage also inhibited cysteamine-stimulated acid secretion."( Effects of a gastric antisecretory-cytoprotectant 2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-acetonitrile (Sch 28 080) on cysteamine, reserpine and stress ulcers in rats.
Barnett, A; Brown, AD; Chiu, PJ; Gerhart, C, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazopyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nrf2Homo sapiens (human)Potency25.92900.09208.222223.1093AID624149
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686979
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00110.540617.639296.1227AID2364; AID2528
hexokinase-4 isoform 1Homo sapiens (human)Potency28.18382.511913.800328.1838AID743205
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency60.119823.934123.934123.9341AID1967
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency1.19950.134610.395030.1313AID1347049
glucokinase regulatory proteinHomo sapiens (human)Potency28.18382.511913.800328.1838AID743205
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
DNA polymerase kappa isoform 1Homo sapiens (human)Potency6.70160.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency19.95260.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)2.00000.00011.774010.0000AID468397
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)10.50000.00011.753610.0000AID468401; AID468402
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)82.00000.00002.015110.0000AID468400
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)54.00000.00002.800510.0000AID468398
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)100.00000.00002.398310.0000AID468399
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (107)

Assay IDTitleYearJournalArticle
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1910987Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A339S mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910981Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A123V mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID183829Antisecretory activity of intraperitoneally injected compound (40 mg/kg) in pylorus-ligated rat1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID78725Compound was evaluated for the ability to inhibit purified H+/K+ -ATPase at pH 7.4, by using gastric membrane vesicles prepared from hog stomach.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID59342Histopathology of the stomach was determined as HGM (Hyperplasia of grandular mucosa)in the presence of the compound.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID178863Antisecretory activity in gastric fistula rat when administered perorally1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and biological activity of 3-substituted imidazo[1,2-a]pyridines as antiulcer agents.
AID60560Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 2 mg/kg given intravenously1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID468397Inhibition of CYP1A22009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID176373Cytoprotective activity against ethyle alcohol induced ulcers was determined in rats by peroral administration of the compound1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID183827Antisecretory activity in pylorus ligated rats at a 40 mg/kg dose administered intraperitoneally1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID78875Inhibition of purified H+/K+ ATPase at pH 7.4 as released inorganic phosphate from ATP using hog stomach gastric membrane vesicles1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies
AID60425Organ weight ratio was determined for the compound with respect to (8-Benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl) compound1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID468408Intrinsic clearance in human liver microsomes2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60561Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 2 mg/kg given orally1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID59824Effective dose required to reduce acid out put when administered perorally in dog;Value ranges from(2.1-14)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID60554Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 2 mg/kg compound administered perorally1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID468401Inhibition of CYP3A4 using diethoxyfluorescein substrate2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60553Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 2 mg/kg i.v.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID159535In vitro inhibition of [14C]- aminopyrine accumulation was determined in gastric vesicles of pig with outside vesicle pH 71990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogues of 4-(arylamino)quinolines.
AID468409Dissociation constant, pKa of the compound2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID59997Inhibition of gastric acid secretion stimulated by histamine in dog was determined by peroral administration confidence limits (p=0.05.); value ranges from 2.1-14.01987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID60565Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 5 mg/kg given intravenously1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID59471Antisecretory activity in histamine stimulated dogs at 5 mg/kg dose administered orally measured as 50% effective concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID176440Oral gastric cytoprotective activity in the rat against ethanol-induced lesions1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID59818Effective dose required to reduce acid out put when administered intravenously in dog;Value ranges from(0.01-1.2).1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID59665Effective dose against histamine stimulated gastric acid secretion in adult mongrel dogs given orally; value ranges from 2.1-14.01985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID59663Effective dose against histamine stimulated gastric acid secretion in adult mongrel dogs given intravenously; value ranges from 0.01-1.191985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID176523Cytoprotective activity in rats against the ethyl alcohol stimulated ulcers measured as effective dose1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID60072Antisecretory activity in histamine stimulated dogs at 2 mg/kg dose administered orally1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID178206Effective dose inhibiting ethanol-induced lesions was determined 1 h, after oral administration of absolute ethanol in rat1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID60073Antisecretory activity in histamine stimulated dogs at 4 mg/kg dose administered orally1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID468400Inhibition of CYP2D62009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID78910Inhibition of H+/K+ ATPase as reduced acid formation in rabbit gastric glands1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies
AID78726Compound was evaluated for the ability to inhibit H+/K+ -ATPase formation in rabbit gastric glands.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID1910991Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910980Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta subunit in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910979Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A339S mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID25103Dissociation constant (pKa)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies
AID1910995Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha I816F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910990Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID183520Cytoprotective activity in rat when administered 30 mg/kg perorally (Ethyl alcohol as necrotic agent)1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and biological activity of 3-substituted imidazo[1,2-a]pyridines as antiulcer agents.
AID1910983Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha V331F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID183525Cytoprotective activity in rats when administered 100 mg/kg perorally (Hydrochloric acid as necrotic agent)1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and biological activity of 3-substituted imidazo[1,2-a]pyridines as antiulcer agents.
AID60555Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 4 mg/kg administered perorally1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID1910989Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799A mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910994Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha I816F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910982Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A123V mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID60423Organ weight (stomach) was determined after administration of the compound1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID468406Intrinsic clearance in rat liver microsomes2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60559Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 1 mg/kg given intravenously1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID60551Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 0.1 mg/kg compound administered intravenously1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID60068Antisecretory activity in histamine stimulated dogs at 0.1 mg/kg dose administered intravenously1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID1910993Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha L809F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID60552Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 1 mg/kg i.v.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID468402Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID183857Gastric antisecretory activity in the pylorus-ligated rat and the reduction in acid output was measured after 4 hr by intraperitoneal (ip) administration of 40 mg/kg dose.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID78903In vitro inhibition of H+/K+ ATPase activity was determined in gastric vesicles of pig using ATPase assay with pH 71990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogues of 4-(arylamino)quinolines.
AID78728The percent of compound protonated at pH 7.4 in purified H+/K+ -ATPase from rabbit gastric glands.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID221913Inhibitory activity against histamine-stimulated gastric acid secretion in adult mengrel dogs, with surgically prepared Heidenhain pouches after peroral administration1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID468399Inhibition of CYP2C192009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60558Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 0.1 mg/kg given intravenously1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID60074Antisecretory activity in histamine stimulated dogs following 5 mg/kg i.v. administration.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID60556Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 5 mg/kg i.v.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID1910992Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha L809F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID59469Antisecretory activity in histamine stimulated dogs at 5 mg/kg dose administered intravenously1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID468398Inhibition of CYP2C92009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID468410Chromatographic hydrophobicity index at pH 7.4 by fast gradient HPLC2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60562Inhibition of histamine stimulated gastric acid secretion in mongrel dogs following 4 mg/kg p.o. administration.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID60069Antisecretory activity in histamine stimulated dogs at 1 mg/kg dose administered intravenously1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID60070Antisecretory activity in histamine stimulated dogs at 2 mg/kg dose administered intravenously1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID60568Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at dose 8 mg/kg given orally1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
AID468396Inhibition of H+/K+ ATPase in parietal cells assessed as inhibition of pentagastrin-stimulated [14C]aminopyrine accumulation2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID60075Antisecretory activity in histamine stimulated dogs at 8 mg/kg dose administered orally1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.
AID1910984Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha V331F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910985Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A335V mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID60011Intravenous effective dose for gastric antisecretory activity against histamine-stimulated gastric acid secretion in adult mongrel dogs1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies
AID1910986Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A335V mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID60025Peroral effective dose for gastric antisecretory activity against histamine-stimulated gastric acid secretion in adult mongrel dogs1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies
AID1910988Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799A mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID468395Inhibition of H+/K+ ATPase at pH 7.42009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID221785Inhibitory activity against histamine-stimulated gastric acid secretion in adult mengrel dogs, with surgically prepared Heidenhain pouches after intravenous administration1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID26399pKa value of the compound.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
AID60424Organ weight ratio was determined for the compound :control1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine.
AID60557Inhibition of histamine stimulated gastric acid secretion in adult mongrel dogs at 8 mg/kg compound administered perorally1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
AID177135In vivo antisecretory activity was determined for inhibition of gastric secretion in rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogues of 4-(arylamino)quinolines.
AID468403Inhibition of CYP3A4 assessed as ratio of IC50 at 0 mins to IC50 at 10 mins using diethoxyfluorescein substrate2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (214)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (16.36)18.7374
1990's100 (46.73)18.2507
2000's52 (24.30)29.6817
2010's20 (9.35)24.3611
2020's7 (3.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.88 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other214 (98.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]